News

Sildenafil Increases Exercise Capacity, Study Suggests

Sildenafil improves how muscles work when patients with cystic fibrosis (CF) exercise and this translates into better exercise capacity, a new study suggests. The study, “Exercise intolerance in cystic fibrosis: importance of skeletal muscle,” was published in the journal Medicine & Science in Sports &…

EU, UK Considering Expanding Kaftrio to Children Ages 6 and Older

Regulatory agencies in the European Union and in the U.K agreed to consider expanding the use of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to children with cystic fibrosis (CF) who have at least one F508del mutation starting at age 6. The European Medicines Agency (EMA) and the U.K.’s Medicines…

Vertex, Concert Strike Deal on Investigational Therapy VX-561

Vertex Pharmaceuticals has made a $32 million purchase from Concert Pharmaceuticals related to future milestones from the 2017 agreement when Vertex purchased Concert’s investigational treatment for cystic fibrosis (CF), VX-561. According to Roger Tung, PhD, Concert’s president and CEO, the purchase will help Concert as it continues…

SpliSense Raises $28.5M to Advance Treatments for Rare CF Mutations

SpliSense has raised $28.5 million in funding to advance its antisense oligonucleotide (ASO) platform for the treatment of cystic fibrosis (CF) caused by certain rare mutations, and of other genetic lung diseases. ASOs are molecules designed to target the messenger RNA (mRNA), the intermediate molecule derived from DNA that guides protein production. Money…

Tobramycin Given in Nanoparticles May Best Treat P. aeruginosa

A new biomaterial made up of nanoparticles showed a potential to improve — by up to 100,000 times — the efficiency of tobramycin, an antibiotic used to treat cystic fibrosis (CF) patients with Pseudomonas aeruginosa infections. Tobramycin, carried within a nanostructured material, completely eradicated P. aeruginosa infection in a…